INDIAN DRUGS,
Год журнала:
2024,
Номер
61(01), С. 70 - 76
Опубликована: Янв. 28, 2024
Glioblastoma
(GBM)
is
a
frequent
as
well
violent
type
of
brain
tumor.
In
this
research
work,
different
carmustine
formulations
were
prepared
and
screened
for
their
cytotoxic
activity
against
U-87
MG
glioblastoma
normal
human
fibroblast
L-929
cell
lines.
The
flexible
liposomes
embedded
in
situ
nasal
gel
exhibited
maximum
percentage
growth
inhibition
line,
lowest
Flexible
observed
to
be
safe
biocompatible
line.
cellular
uptake
study,
line
treated
with
thermoreversible
intranasal
emitted
stronger
higher
intensity
fluorescence.
It
seems
that
the
presence
inside
tumor
cells,
would
best
delivery
approach
management
GBM.
Pharmaceutics,
Год журнала:
2023,
Номер
15(6), С. 1746 - 1746
Опубликована: Июнь 15, 2023
Chronic
ocular
diseases
can
seriously
impact
the
eyes
and
could
potentially
result
in
blindness
or
serious
vision
loss.
According
to
most
recent
data
from
WHO,
there
are
more
than
2
billion
visually
impaired
people
world.
Therefore,
it
is
pivotal
develop
sophisticated,
long-acting
drug
delivery
systems/devices
treat
chronic
eye
conditions.
This
review
covers
several
nanocarriers
that
control
disorders
non-invasively.
However,
of
developed
still
preclinical
clinical
stages.
Long-acting
systems,
such
as
inserts
implants,
constitute
majority
clinically
used
methods
for
treatment
due
their
steady
state
release,
persistent
therapeutic
activity,
ability
bypass
barriers.
implants
considered
invasive
technologies,
especially
those
nonbiodegradable.
Furthermore,
vitro
characterization
approaches,
although
useful,
limited
mimicking
truly
representing
vivo
environment.
focuses
on
systems
(LADDS),
particularly
implantable
(IDDS),
formulation,
characterization,
application
diseases.
Journal of Ocular Pharmacology and Therapeutics,
Год журнала:
2024,
Номер
40(5), С. 261 - 280
Опубликована: Апрель 24, 2024
Ocular
disorders
can
lead
to
serious
sight
impairment
and
irreversible
blindness.
Generally
simple
topical
systemic
treatments
are
recommended
for
treating
these
vision-threatening
illnesses.
The
distinctive
architecture
of
the
eye
complicates
ocular
drug
delivery.
ophthalmic
emulsion
formulations
have
been
found
increase
bioavailability
in
by
prolonging
residence
time
improving
permeability
through
cornea.
Therefore,
this
study
highlights
emulsions
meant
both
anterior
posterior
parts
while
examining
a
wide
range
that
affect
individuals
globally.
This
review
presents,
brief,
recent
emulsion-based
patented
innovations,
clinical
trials,
marketed
delivery,
which
strengthening
development
new
products
managing
different
diseases
disorders.
Journal of Biomedical Materials Research Part B Applied Biomaterials,
Год журнала:
2025,
Номер
113(2)
Опубликована: Янв. 31, 2025
Inflammation
is
a
critical
component
in
the
progression
of
various
ocular
diseases,
such
as
age-related
macular
degeneration,
diabetic
retinopathy,
and
uveitis,
leading
to
significant
vision
loss.
Colchicine
has
been
used
for
treating
gout
with
its
anti-inflammatory
effect.
However,
free
colchicine
demonstrated
cytotoxicity
cells
cannot
directly
be
eye
disease.
Thus,
this
study
introduces,
first
time,
development
use
colchicine-encapsulated
liposomes
novel
therapeutic
approach
managing
inflammation-driven
conditions.
The
encapsulation
within
represents
innovation,
aimed
at
enhancing
biocompatibility
efficacy
while
minimizing
cytotoxic
effects
associated
colchicine.
Our
research
synthesized
colchicine-loaded
assessed
their
impact
on
human
monocytes,
macrophages,
retinal
pigment
epithelium
(RPE)
an
inflammatory
environment.
findings
reveal
groundbreaking
improvement
treatment
strategies,
substantial
reduction
TNF-alpha-induced
reactive
oxygen
species
(ROS)
nitric
oxide
(NO)
production
RPE
cells.
Moreover,
significantly
inhibited
proliferation
ROS
activated
monocytes
macrophages
effectively
decreased
interleukin
(IL)-1β
IL-6
secretion,
highlighting
strong
properties
showed
slightly
better
suppression
these
two
cytokines
than
dexamethasone-liposomes.
The
special
structure
of
eyes
and
the
existence
various
physiological
barriers
make
ocular
drug
delivery
one
most
difficult
problems
in
pharmaceutical
field.
Considering
patient
compliance,
local
administration
remains
preferred
method
anterior
part
eyes.
However,
suffers
from
poor
bioavailability,
need
for
frequent
administration,
systemic
toxicity.
Administration
posterior
eye
is
more
difficult,
intravitreal
injection
often
used.
But
faces
compliance
likely
side
effects
after
multiple
injections.
development
nanocarrier
technology
provides
an
effective
way
to
solve
these
problems.
Among
them,
liposomes,
as
widely
used
carrier
clinical
application,
have
characteristics
amphiphilic
nanostructure,
easy
surface
modification,
extended
release
time,
good
biocompatibility,
etc.
liposomes
are
expected
overcome
obstacles
effectively
deliver
drugs
target
site
improve
bioavailability.
This
review
summarized
controllable
properties
well
application
research
progress
diseases.
In
addition,
we
routes
contained
eyes,
prospects
treatment
